Angela María Londoño-García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Angela María Londoño-García has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Juan Raúl Castro-Ayarza
Dermatology Postgraduate Program, Faculty of Medicine, National University of Colombia, Bogota, Colombia
11 shared publications - Linda Ibatá
EpiThink Health Consulting Bogotá Colombia
7 shared publications - Paola Jimena Cárdenas Rojas
Medicarte IPS Bogotá Colombia
7 shared publications - Susan Martínez
Epidemiology Department, Epithink Health Consulting, Bogotá, Colombia
7 shared publications - Julieth Carolina Castillo
Epidemiology Department, Epithink Health Consulting, Bogotá, Colombia
6 shared publications - Carolina Cortés Correa
Hospital Universitario de la Samaritana, Bogotá, Colombia
5 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5)
Clinical practice guideline for psoriasis management in Latin America
- 29 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5)
Open AccessClinical practice guideline for psoriasis management in Latin America
- 10 July 2026
- Published by Wiley in International Journal of Dermatology
Treat‐To‐Target Goals for Atopic Dermatitis in Colombia: A Modified Delphi Consensus From the Colombian Group of Psoriasis and Immunodermatology ( COLPSOR )
Atopic dermatitis causes substantial symptom burden and impaired quality of life. Treat‐to‐target strategies can improve care by linking management decisions to explicit therapeutic goals, but Colombia lacks a consensus framework for routine practice. We conducted a modified Delphi consensus with 22 Colombian specialists in atopic dermatitis. Two anonymous voting rounds were informed by a systematic literature review. Governance safeguards, conflict‐of‐interest management, and sponsor noninvolvement were prespecified. Main targets and timelines were classified with a simplified evidence‐level and recommendation‐strength framework. The panel defined acceptable and optimal therapeutic targets using clinician‐reported measures and patient‐reported outcome measures. Eczema Area and Severity Index (EASI)‐based thresholds and core symptom and quality‐of‐life instruments were supported by higher‐quality evidence, whereas follow‐up intervals, implementation strategies, and some adjunct measures relied more on expert consensus and contextual adaptation. The framework links response thresholds to reassessment timelines and treatment decisions for routine care. This consensus provides a practical treat‐to‐target framework for atopic dermatitis in Colombia and a model that may inform adaptation in other health systems. image
- 10 July 2026
- Published by Wiley in International Journal of Dermatology
Treat‐To‐Target Goals for Atopic Dermatitis in Colombia: A Modified Delphi Consensus From the Colombian Group of Psoriasis and Immunodermatology ( COLPSOR )
Atopic dermatitis causes substantial symptom burden and impaired quality of life. Treat‐to‐target strategies can improve care by linking management decisions to explicit therapeutic goals, but Colombia lacks a consensus framework for routine practice. We conducted a modified Delphi consensus with 22 Colombian specialists in atopic dermatitis. Two anonymous voting rounds were informed by a systematic literature review. Governance safeguards, conflict‐of‐interest management, and sponsor noninvolvement were prespecified. Main targets and timelines were classified with a simplified evidence‐level and recommendation‐strength framework. The panel defined acceptable and optimal therapeutic targets using clinician‐reported measures and patient‐reported outcome measures. Eczema Area and Severity Index (EASI)‐based thresholds and core symptom and quality‐of‐life instruments were supported by higher‐quality evidence, whereas follow‐up intervals, implementation strategies, and some adjunct measures relied more on expert consensus and contextual adaptation. The framework links response thresholds to reassessment timelines and treatment decisions for routine care. This consensus provides a practical treat‐to‐target framework for atopic dermatitis in Colombia and a model that may inform adaptation in other health systems. image
- Open Access
- 1 June 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (7) , 1026-1031
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease
Certain psoriatic disease treatments, including tumor necrosis factor‐α inhibitors (TNFi), increase tuberculosis (TB) risk. Testing for latent TB infection (LTBI) before initiating systemic therapy has been standard practice for psoriasis (PsO) patients; however, updated consensus states routine testing is not required before initiating interleukin (IL)‐17 or IL‐23 inhibitors. This analysis reports safety outcomes in LTBI+ patients with moderate‐to‐severe PsO or active psoriatic arthritis (PsA) who received guselkumab for up to 5 years. Data were pooled from 11 phase 2/3 studies (7 PsO, 4 PsA). Guselkumab 100 mg was generally administered at Week 0, Week 4, then every 8 weeks (PsO studies) or every 4 or 8 weeks (PsA studies). Placebo‐randomized patients crossed over to guselkumab at Week 16 and Week 24 in PsO and PsA studies, respectively. Patients with active TB or a history of active TB were excluded. LTBI+ patients could participate if LTBI treatment was initiated before/with the first dose of study drug or if LTBI treatment was completed within 5 years before the first dose of study drug. Among 5 255 randomized patients, 374 (7.1%) had LTBI and received preventive treatment, most commonly isoniazid (82.1%) and rifampicin (11.8%). No new‐onset TB or LTBI reactivation occurred in any guselkumab‐treated patient. Through Year 1, liver transaminase elevations were more common in LTBI+ vs. LTBI− patients; ≤ 2% of LTBI+ patients had CTCAE Grade 3 elevations vs. 0.5% of LTBI− patients (no LTBI+ patients had Grade 4 elevations). From Year 1–5 (after ~98% of LTBI+ patients completed preventive treatment), transaminase elevations were generally similar among LTBI+ and LTBI− patients. The absence of observed TB risk in guselkumab‐treated patients suggests IL‐23 inhibitors may be better treatment options than TNFi in high‐risk patients, including those in TB‐endemic regions.
- 1 June 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (7) , 1026-1031
Open AccessGuselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease
Certain psoriatic disease treatments, including tumor necrosis factor‐α inhibitors (TNFi), increase tuberculosis (TB) risk. Testing for latent TB infection (LTBI) before initiating systemic therapy has been standard practice for psoriasis (PsO) patients; however, updated consensus states routine testing is not required before initiating interleukin (IL)‐17 or IL‐23 inhibitors. This analysis reports safety outcomes in LTBI+ patients with moderate‐to‐severe PsO or active psoriatic arthritis (PsA) who received guselkumab for up to 5 years. Data were pooled from 11 phase 2/3 studies (7 PsO, 4 PsA). Guselkumab 100 mg was generally administered at Week 0, Week 4, then every 8 weeks (PsO studies) or every 4 or 8 weeks (PsA studies). Placebo‐randomized patients crossed over to guselkumab at Week 16 and Week 24 in PsO and PsA studies, respectively. Patients with active TB or a history of active TB were excluded. LTBI+ patients could participate if LTBI treatment was initiated before/with the first dose of study drug or if LTBI treatment was completed within 5 years before the first dose of study drug. Among 5 255 randomized patients, 374 (7.1%) had LTBI and received preventive treatment, most commonly isoniazid (82.1%) and rifampicin (11.8%). No new‐onset TB or LTBI reactivation occurred in any guselkumab‐treated patient. Through Year 1, liver transaminase elevations were more common in LTBI+ vs. LTBI− patients; ≤ 2% of LTBI+ patients had CTCAE Grade 3 elevations vs. 0.5% of LTBI− patients (no LTBI+ patients had Grade 4 elevations). From Year 1–5 (after ~98% of LTBI+ patients completed preventive treatment), transaminase elevations were generally similar among LTBI+ and LTBI− patients. The absence of observed TB risk in guselkumab‐treated patients suggests IL‐23 inhibitors may be better treatment options than TNFi in high‐risk patients, including those in TB‐endemic regions.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Drug Survival of Biologic Therapy for Moderate‐to‐Severe Psoriasis in a Latin American Specialized Psoriasis Center: A 7‐Year Experience
Background: Drug survival integrates effectiveness, safety, and access in routine psoriasis care, yet real‐world Latin American data are scarce. We assessed drug survival and explanatory factors of discontinuation among bio‐naïve adults with moderate‐to‐severe psoriasis in Colombia. Methods: We conducted a retrospective cohort study using secondary electronic health record data from a multidisciplinary clinic in Medellín, Colombia (CLIPSO) from January 2018 to December 2024. Eligible adults met at least one severity criterion (PASI ≥ 10, BSA ≥ 10, or DLQI ≥ 10), initiated a first biologic, and had ≥ 3 months of treatment. Drug survival was the time from initiation to discontinuation for any reason. Records with > 60% missing data underwent targeted chart review to verify key variables. Kaplan–Meier curves (log‐rank) and Cox proportional hazards models were used. Results: The cohort included 1098 patients (48.8% women); 30.1% discontinued therapy. Therapeutic failure was the leading reason (58.2%), whereas adverse events were less frequently reported (11.2%). Drug survival declined to ∼50% at 60 months and ∼43% by 80 months. In multivariable analyses, adalimumab showed higher discontinuation risk (aHR = 1.36; 95% CI: 1.0001–1.84), whereas risankizumab (aHR = 0.41; 95% CI: 0.21–0.80), guselkumab (aHR = 0.42; 95% CI: 0.26–0.68), ixekizumab (aHR = 0.59; 95% CI: 0.41–0.85), and secukinumab (aHR = 0.67; 95% CI 0.47–0.97) showed better persistence. The presence of a high burden of comorbidities increased risk (aHR = 1.71; 95% CI: 1.12–2.63), whereas prior systemic therapy was protective (aHR = 0.45; 95% CI: 0.28–0.72). Conclusions: Drug survival differed across biologics in this Colombian real‐world cohort, with interleukin‐23 and interleukin‐17 inhibitors demonstrating greater persistence in both bivariate and multivariable models and comorbidity burden identifying patients at higher risk of discontinuation.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessDrug Survival of Biologic Therapy for Moderate‐to‐Severe Psoriasis in a Latin American Specialized Psoriasis Center: A 7‐Year Experience
Background: Drug survival integrates effectiveness, safety, and access in routine psoriasis care, yet real‐world Latin American data are scarce. We assessed drug survival and explanatory factors of discontinuation among bio‐naïve adults with moderate‐to‐severe psoriasis in Colombia. Methods: We conducted a retrospective cohort study using secondary electronic health record data from a multidisciplinary clinic in Medellín, Colombia (CLIPSO) from January 2018 to December 2024. Eligible adults met at least one severity criterion (PASI ≥ 10, BSA ≥ 10, or DLQI ≥ 10), initiated a first biologic, and had ≥ 3 months of treatment. Drug survival was the time from initiation to discontinuation for any reason. Records with > 60% missing data underwent targeted chart review to verify key variables. Kaplan–Meier curves (log‐rank) and Cox proportional hazards models were used. Results: The cohort included 1098 patients (48.8% women); 30.1% discontinued therapy. Therapeutic failure was the leading reason (58.2%), whereas adverse events were less frequently reported (11.2%). Drug survival declined to ∼50% at 60 months and ∼43% by 80 months. In multivariable analyses, adalimumab showed higher discontinuation risk (aHR = 1.36; 95% CI: 1.0001–1.84), whereas risankizumab (aHR = 0.41; 95% CI: 0.21–0.80), guselkumab (aHR = 0.42; 95% CI: 0.26–0.68), ixekizumab (aHR = 0.59; 95% CI: 0.41–0.85), and secukinumab (aHR = 0.67; 95% CI 0.47–0.97) showed better persistence. The presence of a high burden of comorbidities increased risk (aHR = 1.71; 95% CI: 1.12–2.63), whereas prior systemic therapy was protective (aHR = 0.45; 95% CI: 0.28–0.72). Conclusions: Drug survival differed across biologics in this Colombian real‐world cohort, with interleukin‐23 and interleukin‐17 inhibitors demonstrating greater persistence in both bivariate and multivariable models and comorbidity burden identifying patients at higher risk of discontinuation.
- Open Access
- 22 September 2025
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 45 (4) , 566-573
Incidence and prevalence of vitiligo by gender and age in the Colombian population
Introduction. Vitiligo is an acquired depigmenting skin disorder characterized by achromic macules resulting from the selective destruction of melanocytes. Epidemiological information regarding this condition remains limited in Colombia and Latin America, with prevalence varying across geographical regions.Objective. To estimate the incidence and prevalence of vitiligo in Colombia by age, gender, and region.Materials and methods. A retrospective study was conducted utilizing real-world clinical practice data retrieved from the national registry SISPRO (Sistema de Información para la Protección Social) spanning the period from 2015 to 2022.Results. Over the eight-year follow-up period (2015-2022) in Colombia, 131,494 patients were diagnosed with vitiligo. In 2016, the lowest incidence was observed, with 26 cases per 100,000 inhabitants, whereas in 2019, the highest incidence was recorded at 47 cases per 100,000 inhabitants, representing a difference of 11,175 cases between the two years. Incidence decreased in 2020 to 28.15 cases per 100,000 inhabitants. Prevalence exhibited a linear increase over the years, with the highest rates observed in 2018 and 2019.Conclusions. This study represents the first comprehensive report on epidemiological data concerning individuals with vitiligo in Colombia, and the second in South America. It contributes to the understanding of this condition, revealing an upward trend in incidence and prevalence. These findings also provide insights into primary treatment modalities, which are probably associated with improved case registration by healthcare providers.
- 22 September 2025
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 45 (4) , 566-573
Open AccessIncidence and prevalence of vitiligo by gender and age in the Colombian population
Introduction. Vitiligo is an acquired depigmenting skin disorder characterized by achromic macules resulting from the selective destruction of melanocytes. Epidemiological information regarding this condition remains limited in Colombia and Latin America, with prevalence varying across geographical regions.Objective. To estimate the incidence and prevalence of vitiligo in Colombia by age, gender, and region.Materials and methods. A retrospective study was conducted utilizing real-world clinical practice data retrieved from the national registry SISPRO (Sistema de Información para la Protección Social) spanning the period from 2015 to 2022.Results. Over the eight-year follow-up period (2015-2022) in Colombia, 131,494 patients were diagnosed with vitiligo. In 2016, the lowest incidence was observed, with 26 cases per 100,000 inhabitants, whereas in 2019, the highest incidence was recorded at 47 cases per 100,000 inhabitants, representing a difference of 11,175 cases between the two years. Incidence decreased in 2020 to 28.15 cases per 100,000 inhabitants. Prevalence exhibited a linear increase over the years, with the highest rates observed in 2018 and 2019.Conclusions. This study represents the first comprehensive report on epidemiological data concerning individuals with vitiligo in Colombia, and the second in South America. It contributes to the understanding of this condition, revealing an upward trend in incidence and prevalence. These findings also provide insights into primary treatment modalities, which are probably associated with improved case registration by healthcare providers.
- 15 August 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (12) , 1302-1311
Establishing Centers of Excellence for Psoriatic Disease in Latin America: Consensus Recommendations From the REAL-PANLAR Group
Objective: Psoriatic disease (PsD) is a chronic, multisystem, inflammatory condition characterized by heterogeneous manifestations, including peripheral arthritis, axial involvement, enthesitis, and cutaneous and nail psoriasis. The condition has significant physical, emotional, and psychosocial effects on patients. In Latin America, healthcare disparities exacerbate delays in diagnosis and treatment, increasing the burden of PsD and associated comorbidities. This study aimed to establish regionally adapted criteria for Centers of Excellence (COEs) to optimize PsD care. Methods: A panel of 18 experts in rheumatology and dermatology from 12 Latin American countries developed COE criteria using the Delphi methodology. A narrative literature review informed the process, and criteria were evaluated using a Likert scale. Consensus was defined as ≥ 70% agreement, and an in-person meeting refined unresolved items. The criteria were categorized into structure, process, and outcomes, based on the Donabedian quality evaluation model. Results: Two types of COEs were defined: optimal and model. Optimal COEs require a multidisciplinary team including rheumatologists, dermatologists, nurses, and psychologists. Model COEs expand this team to include gastroenterologists, ophthalmologists, physiatrists, among other specialists. Structural criteria emphasized infrastructure and electronic systems for data management. Process criteria included patient-centered education, multidisciplinary consultations, and psychosocial support. Outcomes focused on standardized clinimetric tools (eg, Psoriasis Area and Severity Index, Disease Activity Index for Psoriatic Arthritis) and the treat-to-target strategy. Approval ratings ranged from 80% to 100%. Conclusion: The consensus establishes a framework for COEs in PsD care in Latin America, addressing structural, process, and outcome criteria to improve clinical outcomes, patient satisfaction, and healthcare system sustainability. These standards provide a roadmap for enhancing PsD management in resource-limited settings.
- 15 August 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (12) , 1302-1311
Establishing Centers of Excellence for Psoriatic Disease in Latin America: Consensus Recommendations From the REAL-PANLAR Group
Objective: Psoriatic disease (PsD) is a chronic, multisystem, inflammatory condition characterized by heterogeneous manifestations, including peripheral arthritis, axial involvement, enthesitis, and cutaneous and nail psoriasis. The condition has significant physical, emotional, and psychosocial effects on patients. In Latin America, healthcare disparities exacerbate delays in diagnosis and treatment, increasing the burden of PsD and associated comorbidities. This study aimed to establish regionally adapted criteria for Centers of Excellence (COEs) to optimize PsD care. Methods: A panel of 18 experts in rheumatology and dermatology from 12 Latin American countries developed COE criteria using the Delphi methodology. A narrative literature review informed the process, and criteria were evaluated using a Likert scale. Consensus was defined as ≥ 70% agreement, and an in-person meeting refined unresolved items. The criteria were categorized into structure, process, and outcomes, based on the Donabedian quality evaluation model. Results: Two types of COEs were defined: optimal and model. Optimal COEs require a multidisciplinary team including rheumatologists, dermatologists, nurses, and psychologists. Model COEs expand this team to include gastroenterologists, ophthalmologists, physiatrists, among other specialists. Structural criteria emphasized infrastructure and electronic systems for data management. Process criteria included patient-centered education, multidisciplinary consultations, and psychosocial support. Outcomes focused on standardized clinimetric tools (eg, Psoriasis Area and Severity Index, Disease Activity Index for Psoriatic Arthritis) and the treat-to-target strategy. Approval ratings ranged from 80% to 100%. Conclusion: The consensus establishes a framework for COEs in PsD care in Latin America, addressing structural, process, and outcome criteria to improve clinical outcomes, patient satisfaction, and healthcare system sustainability. These standards provide a roadmap for enhancing PsD management in resource-limited settings.
- Open Access
- 7 July 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (4)
Consenso latino‐americano sobre redução gradual da terapia biológica na psoríase
- 7 July 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (4)
Open AccessConsenso latino‐americano sobre redução gradual da terapia biológica na psoríase
- Open Access
- 18 June 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (4) , 501134
Latin American consensus on tapering of biological therapy in psoriasis
- 18 June 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (4) , 501134
Open AccessLatin American consensus on tapering of biological therapy in psoriasis
- Open Access
- 30 May 2025
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 45 (2) , 310-320
Psoriasis en población pediátrica: un estudio descriptivo, retrospectivo y multicéntrico en Colombia
Introducción. La psoriasis pediátrica tiene una prevalencia del 0,5 al 4,1 %. Es más frecuente en el sexo femenino y predomina su variante vulgar o en placa. Se ha relacionado con comorbilidades como la obesidad y el síndrome metabólico, e incluso, con antecedentes familiares de psoriasis.Objetivo. Describir las características epidemiológicas y clínicas de los pacientes pediátricos con diagnóstico de psoriasis que consultaron a dermatólogos miembros de la Asociación Colombiana de Dermatología, de enero de 2017 a junio de 2022. Materiales y métodos. Se trata de un estudio descriptivo, retrospectivo y multicéntrico, en el cual se determinó la prevalencia de la psoriasis, y se describen las características clínicas, el método diagnóstico, los antecedentes personales y familiares, y los tratamientos en casos pediátricos. Las variables se analizaron con el programa Stata 13™. Resultados. De 26.870 pacientes pediátricos atendidos, 146 tuvieron diagnóstico de psoriasis (0,54% de prevalencia), con una relación entre mujeres y hombres de 1,5:1. La mediana de la edad de aparición fue de ocho años. La variante más común fue la vulgar (72,6 %), seguida de la guttata (6,85 %). El cuero cabelludo fue la localización más frecuente (55,48 %). Las comorbilidades más comunes fueron obesidad y enfermedad de Crohn (5,5 % cada una). En cuanto a antecedentes familiares, se reportaron 39 casos de psoriasis, 16 de diabetes mellitus y 7 de dislipidemia. El 78 % fueron reportados como leves, según el Psoriasis Area Severity Index (PASI). El 65 % de los pacientes recibió tratamiento tópico, el 18 %, sistémico y, el 2,7 %, fototerapia; en cuanto a tratamientos combinados, el 6 % recibió el tópico y sistémico, el 1,3%, el tópico más fototerapia, y el 0,68 % recibió la combinación de todos.Conclusiones. En la población evaluada, la variante de psoriasis pediátrica más frecuente fue la vulgar en su forma leve y, en la mayoría de los casos, el tratamiento fue tópico. La asociación ocasional con otras enfermedades sistémicas, como obesidad y síndrome metabólico, implica la necesidad de ampliar los estudios.
- 30 May 2025
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 45 (2) , 310-320
Open AccessPsoriasis en población pediátrica: un estudio descriptivo, retrospectivo y multicéntrico en Colombia
Introducción. La psoriasis pediátrica tiene una prevalencia del 0,5 al 4,1 %. Es más frecuente en el sexo femenino y predomina su variante vulgar o en placa. Se ha relacionado con comorbilidades como la obesidad y el síndrome metabólico, e incluso, con antecedentes familiares de psoriasis.Objetivo. Describir las características epidemiológicas y clínicas de los pacientes pediátricos con diagnóstico de psoriasis que consultaron a dermatólogos miembros de la Asociación Colombiana de Dermatología, de enero de 2017 a junio de 2022. Materiales y métodos. Se trata de un estudio descriptivo, retrospectivo y multicéntrico, en el cual se determinó la prevalencia de la psoriasis, y se describen las características clínicas, el método diagnóstico, los antecedentes personales y familiares, y los tratamientos en casos pediátricos. Las variables se analizaron con el programa Stata 13™. Resultados. De 26.870 pacientes pediátricos atendidos, 146 tuvieron diagnóstico de psoriasis (0,54% de prevalencia), con una relación entre mujeres y hombres de 1,5:1. La mediana de la edad de aparición fue de ocho años. La variante más común fue la vulgar (72,6 %), seguida de la guttata (6,85 %). El cuero cabelludo fue la localización más frecuente (55,48 %). Las comorbilidades más comunes fueron obesidad y enfermedad de Crohn (5,5 % cada una). En cuanto a antecedentes familiares, se reportaron 39 casos de psoriasis, 16 de diabetes mellitus y 7 de dislipidemia. El 78 % fueron reportados como leves, según el Psoriasis Area Severity Index (PASI). El 65 % de los pacientes recibió tratamiento tópico, el 18 %, sistémico y, el 2,7 %, fototerapia; en cuanto a tratamientos combinados, el 6 % recibió el tópico y sistémico, el 1,3%, el tópico más fototerapia, y el 0,68 % recibió la combinación de todos.Conclusiones. En la población evaluada, la variante de psoriasis pediátrica más frecuente fue la vulgar en su forma leve y, en la mayoría de los casos, el tratamiento fue tópico. La asociación ocasional con otras enfermedades sistémicas, como obesidad y síndrome metabólico, implica la necesidad de ampliar los estudios.
- Open Access
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 539-547
Consenso latino‐americano sobre classificação da gravidade da psoríase
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 539-547
Open AccessConsenso latino‐americano sobre classificação da gravidade da psoríase